Aurinia Pharmaceuticals Inc.
NASDAQ:AUPHBiotechnology
+$0.13 today
- Market cap
- $2.03B
- Beta
- 1.43
- P/E (TTM)
- 7.2
- EPS (TTM)
- $2.25
Volume 0.76M
Average 1.21M
AUPH Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Aurinia Pharmaceuticals Inc.NASDAQ: AUPH
Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026
Net change in cash turns positive
Q2 FY2026 net change in cash was $138.82M, compared with -$13.43M a year earlier. Trailing-twelve-month net change in cash was $126.83M. Over 3 fiscal years it compounded at -71.4% a year.
Context
- Net change in cash amounted to 1.1% of revenue in FY2025, down 13.6 pp from a year earlier.
- Net change in cash increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly net change in cash holds near $138.82M or moves back toward the trailing-twelve-month quarterly average of $31.71M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (3.22M) USD
- Year-over-year change
- -109.3%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.22M) | -109.3% |
| FY2024 | 2024-12-31 | 34.56M | +176.3% |
| FY2023 | 2023-12-31 | (45.3M) | +67.1% |
| FY2022 | 2022-12-31 | (137.73M) | -240.5% |
| FY2021 | 2021-12-31 | (40.45M) | — |
Net Change in Cash vs competitors
How AUPH compares with its peers on the latest reported figures
- AUPH's LTM Jun 2026 net change in cash of $126.83M is the largest of the 10 companies compared; the peer median is $9.56M.
- Its year-over-year change of +547.3% is the 2nd highest of 9, against a peer median of -18.3%.
- Net change in cash amounts to 40.7% of revenue for AUPH, versus a peer median of 567.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $126.83M | +547.3% | -71.4% | 40.7% | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $115.12M | +32.1% | — | — |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $88.34M | +2748.7% | +2.1% | 1194.1% |
| LTM Jun 2026 | $71.63M | +197.7% | -7.7% | — | |
EVMNEvommune, Inc. | LTM Mar 2026 | $42.61M | — | — | 426.1% |
| LTM Mar 2026 | $26.92M | +114.4% | +69.8% | — | |
| FY2025 | $9.56M | -68.8% | — | 708.2% | |
| LTM Mar 2026 | $2.34M | -182.5% | — | — | |
| LTM Mar 2026 | $1.7M | -69.1% | — | 20.3% | |
| LTM Jun 2026 | $245K | -101.0% | — | — | |
| Peer median (excluding AUPH) | $9.56M | -18.3% | +2.1% | 567.2% | |
Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (180.97M) | (108.18M) | (78.02M) | 5.75M | 287.2M |
| Depreciation & Amortization | 2.76M | 2.71M | 11.65M | 19.45M | 9.27M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (176.19M) |
| Stock-Based Compensation | 31.24M | 32.3M | 45.31M | 31.6M | 14.68M |
| Change in Working Capital | (21.63M) | (6.82M) | (5.61M) | 5.45M | (8.78M) |
| Accounts Receivables | (15.42M) | 1.93M | (10.61M) | (12.46M) | (4.91M) |
| Inventory | (5.64M) | (9.07M) | (15.87M) | 477K | (6.46M) |
| Accounts Payables | 4.08M | (792K) | 1.24M | 860K | (1.87M) |
| Other Working Capital | (4.65M) | 1.12M | 19.63M | 16.57M | 4.46M |
| Other Non-Cash Items | 10.9M | 462K | (6.79M) | (17.85M) | 9.49M |
| Operating Cash Flow | (157.69M) | (79.53M) | (33.46M) | 44.39M | 135.66M |
| Capital Expenditures | (1.5M) | (292K) | (718K) | (281K) | (252K) |
| Acquisitions (Net) | (1.2M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (438.96M) | (523.99M) | (523.5M) | (545.83M) | (526.65M) |
| Sales of Investments | 354.43M | 464.32M | 529.38M | 585.42M | 494.13M |
| Other Investing Activities | (16.63M) | (663K) | (11.86M) | (43K) | 0 |
| Investing Cash Flow | (103.87M) | (60.63M) | (6.71M) | 39.26M | (32.77M) |
| Debt Repayment | 0 | 0 | (10.03M) | (11.99M) | (13.14M) |
| Common Stock Issued | 196.74M | 0 | 0 | 0 | 14.95M |
| Common Stock Repurchased | 0 | 0 | 0 | (40.24M) | (98.16M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 24.37M | 2.43M | 4.9M | 3.14M | (9.76M) |
| Financing Cash Flow | 221.11M | 2.43M | (5.13M) | (49.09M) | (106.11M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (40.45M) | (137.73M) | (45.3M) | 34.56M | (3.22M) |
| Free Cash Flow | (159.19M) | (79.82M) | (34.18M) | 44.11M | 135.41M |
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
Intrinsic Alpha fair value
Locked
Current Price
$15.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.